You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,591,713


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,591,713
Title: Water-soluble composition for sustained-release
Abstract:(1) A composition which comprises erythropoietin and hyaluronic acid shows a sustained-release of the medicine in a living body, and (2) A water-soluble composition which comprises (a) a pharmacologically active polypeptide secreted by an animal body or its derivative or a chemically synthesized pharmacologically active substance, (b) a water-soluble species\' of hyaluronic acid or its nontoxic salt and (c) a water-soluble protein injectable into body fluids without showing any substantial pharmacological activity brings about a prolonged action in vivo of a pharmacologically active substance. In addition, the composition can be administered using a small-gauge needle and thereby contributes to relieving pain in patients.
Inventor(s): Igari; Yasutaka (Kobe, JP), Yamada; Minoru (Kawanishi, JP), Ogawa; Yasuaki (Kyoto, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:08/377,392
Patent Claims:1. A water-soluble composition which comprises (a) a pharmacologically active polypeptide secreted by an animal body or its derivative or a chemically synthesized pharmacologically active substance, (b) a water-soluble species of hyaluronic acid or its non-toxi salt and (c) a water-soluble protein injectable into body fluids without showing any substantial pharmacological activity.

2. A water-soluble composition as claimed in claim 1, wherein the pharmacologically active polypeptide is cytokines, peptide hormones, growth factors, the factors that affect cardiovasculr system, the factors that affect central and peripheral nerve system, the factors that affect body fluid electrolytes and blood organic constituents, the factors that affect bone and skeletal system, the factors that affect gastrointestinal system, the factors that affect immune system, the factors that affect respiratory system, the factors that affect genital system or enzymes, or its mutein, derivative, analog, homolog, or active fragment.

3. A water-soluble composition as claimed in claim 1, wherein the pharmacologically active polypeptide is interferons, interleukins, erythropoietin, granulocyte colony stimulating factor (G-CSF), granylocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), fibroblast growth factor (FGF), tumor necrotizing factor (TNF), parathyroid hormone (PTH), calcitonin, insulin or leutenizing hormone-releasing hormone (LH-RH).

4. A water-soluble composition as claimed in claim 1, wherein the chemically synthesized pharmacologically active substance is those that affect cardiovascular system, those that affect cell attachment, those that affect central and peripheral nerve system, those that affect body fluid electrolytes and blood organic constituents, those that affect bone and skeletal system, those that affect gastrointestinal system, those that affect immune system or those that affect infective microorganisms.

5. A water-soluble composition as claimed in claim 1, wherein the water-soluble protein is human serum albumin.

6. A water-soluble composition as claimed in claim 1, which shows a viscosity of not more than 500 cp in an aqueous solution form.

7. A water-soluble composition as claimed in claim 1, which contains the water-soluble hyaluronic acid in an amount of about 0.01 to 3% (weight to volume).

8. A water-soluble composition as claimed in claim 1, which contains about 0.001 to 5% (weight to volume) of serum albumin as the water-soluble protein.

9. A water-soluble composition as claimed in claim 1, which contains about 0.001 to 5% (weight to volume) of a globulin as the water-soluble protein.

10. A water-soluble composition as claimed in claim 1, which contains about 0.001 to 1% (weight to volume) of collagen as the water-soluble protein.

11. A water-soluble composition as claimed in claim 1, which contains about 0.001 to 1% (weight to volume) of gelatin as the water-soluble protein.

12. A water-soluble composition as claimed in claim 1, which is in the form of preparation for parenteral administration.

13. A water-soluble composition as claimed in claim 12, which is in the form of an injectable preparation.

14. A water-soluble composition as claimed in claim 1, wherein the weight ratio of the pharmacologically active substance to hyaluronic acid or its nontoxic salt is in the range of about 0.0001:1 to about 10:1, and the weight ratio of water-soluble protein to hyaluronic acid or its nontoxic salt is in the range of about 0.001:1 to about 100:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.